174 lines
36 KiB
Text
174 lines
36 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK604847">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK604847/?report=reader">
|
|
<meta name="ncbi_pagename" content="Tafasitamab - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Tafasitamab - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Tafamidis/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Tafenoquine/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Tafasitamab">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2024/05/14">
|
|
<meta name="citation_pmid" content="38985926">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK604847/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Tafasitamab">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2024/05/14">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK604847/">
|
|
<meta name="description" content="Tafasitamab is a cytotoxic monoclonal antibody against CD19 that is used in combination with other antineoplastic agents to treat adults with relapsed or refractory diffuse large B cell lymphoma. Tafasitamab therapy is associated with a low rate of mild serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent liver injury.">
|
|
<meta name="og:title" content="Tafasitamab">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Tafasitamab is a cytotoxic monoclonal antibody against CD19 that is used in combination with other antineoplastic agents to treat adults with relapsed or refractory diffuse large B cell lymphoma. Tafasitamab therapy is associated with a low rate of mild serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK604847/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Tafasitamab/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK604847/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D0CC87C8DD0910000000000780064.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK604847/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Tafamidis/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Tafasitamab</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Tafenoquine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK604847/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK604847/&text=Tafasitamab"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK604847/?report=classic">Switch to classic view</a><a href="/books/NBK604847/pdf/Bookshelf_NBK604847.pdf">PDF (90K)</a><a href="/books/NBK604847/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK604847%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D0CC87C8DD0910000000000780064.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK604847_"><span class="title" itemprop="name">Tafasitamab</span></h1><p class="fm-aai"><a href="#_NBK604847_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Tafasitamab.OVERVIEW"><h2 id="_Tafasitamab_OVERVIEW_">OVERVIEW</h2><div id="Tafasitamab.Introduction"><h3>Introduction</h3><p>Tafasitamab is a cytotoxic monoclonal antibody against CD19 that is used in combination with other antineoplastic agents to treat adults with relapsed or refractory diffuse large B cell lymphoma. Tafasitamab therapy is associated with a low rate of mild serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent liver injury.</p></div><div id="Tafasitamab.Background"><h3>Background</h3><p>Tafasitamab (ta” fa sit’ a mab) is Fc modified, humanized, cytolytic monoclonal antibody against CD19 that is used to treat adults with advanced, relapsed or refractory B cell malignancies, including diffuse large B cell lymphoma (DLBCL). Tafasitamab binds to CD19 which is expressed on pre- and mature B lymphocytes inducing antibody dependent cytolysis or apoptosis. Tafasitamab treatment lowers peripheral B cells, and chronic therapy is effective in inducing remissions in patients with relapsed or refractory B cell lymphomas. Tafasitamab in combination with lenalidomide was approved in the United States in 2020 for treatment of adults with relapsed or refractory DLBCL who are not candidates for autologous hematopoietic stem cell transplant. Tafasitamab is available as a powder for reconstitution in single use vials of 200 mg under the brand name Monjuvi. The recommended dose regimen is 12 mg/kg intravenously on 2 to 5 days of each 28 day course; for the initial 28 day cycle on days 1, 4, 8, 15, and 22, for cycles 2 and 3 on days 1, 8, 15 and 22, and for subsequent cycles on days 1 and 15. Tafasitamab should be administered with daily oral lenalidomide for no more than 12 cycles, but can be continued as monotherapy thereafter. Therapy should be continued until disease progression or unacceptable toxicity occur. Premedication with antihistamines, H2 blockers, or glucocorticoids is recommended. The combination of tafasitamab and lenalidomide has many adverse events that require monitoring and careful management. Common adverse events include neutropenia, anemia, thrombocytopenia, fatigue, cough, pyrexia, peripheral edema, respiratory tract infections, diarrhea, constipation, nausea, decreased appetite, and rash. Serious adverse events include severe myelosuppression, severe infections, infusion site reactions, and embryo-fetal toxicity. Tafasitamab should be administered only by health care providers with knowledge and experience with myelosuppressive immunotherapy of cancer.</p></div><div id="Tafasitamab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In small, preregistration open label trials, serum ALT elevations occurred in 11% of tafasitamab treated subjects but were generally transient and mild, and there were no instances of ALT elevations above 5 times the upper limit of normal (ULN) or clinically apparent liver injury with symptoms or jaundice. Since the approval of tafasitamab in 2020, there have been no case reports of clinically apparent liver injury attributed to its use. Monoclonal antibodies to CD19 have been used for other indications and similarly have been free of liver injury. These B cell directed monoclonal antibodies, however, are considered possible causes of reactivation of hepatitis B and prescreening for hepatitis B status is usually recommended. At least one case of reactivation of hepatitis B was reported in the follow up of the open label registration trial of tafasitamab and lenalidomide therapy.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury except as a result of reactivation of hepatitis B).</p></div><div id="Tafasitamab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The causes of the mild liver test abnormalities during tafasitamab therapy are not clearly known but appear to be related to the underlying condition, other neoplastic agents (lenalidomide for instance) or comorbidities. Tafasitamab can cause hypersensitivity reactions including urticaria and rash, and liver injury might be a part of the immunoallergic reaction. Cases of reactivation of hepatitis B were not observed during prelicensure studies and should not occur with adequate prescreening and prophylaxis against reactivation.</p></div><div id="Tafasitamab.Outcome_and_Management"><h3>Outcome and Management</h3><p>The product label for tafasitamab does not recommend monitoring of routine liver tests during therapy. Nevertheless, if detected, de novo elevations of serum aminotransferase levels above 5 times the ULN or baseline values should lead to temporary discontinuation and evaluation for other possible causes of liver injury, restarting therapy only when values return to normal or near normal and with careful subsequent monitoring. Screening of candidates for therapy for evidence of hepatitis B (for HBsAg and anti-HBc) is appropriate and, if positive, consultation for advice on the need for prophylaxis or prospective monitoring.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/?report=reader">Antineoplastic Agents</a>, <a href="/books/n/livertox/MonoclonalAntibodies/?report=reader">Monoclonal Antibodies</a></p></div></div><div id="Tafasitamab.PRODUCT_INFORMATION"><h2 id="_Tafasitamab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Tafasitamab – Monjuvi®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antineoplastic Agents, Monoclonal Antibodies</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tafasitamab" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Tafasitamab.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Tafasitamab_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figTafasitamabTc"><a href="/books/NBK604847/table/Tafasitamab.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobTafasitamabTc"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Tafasitamab.Tc"><a href="/books/NBK604847/table/Tafasitamab.Tc/?report=objectonly" target="object" rid-ob="figobTafasitamabTc">Table</a></h4></div></div></div><div id="Tafasitamab.SELECTED_BIBLIOGRAPHY"><h2 id="_Tafasitamab_SELECTED_BIBLIOGRAPHY_">SELECTED BIBLIOGRAPHY</h2><p>References updated: 14 May 2024</p><p>Abbreviations: DLBCL, diffuse large B cell lymphoma; ULN, upper limit of the normal range.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Tafasitamab.REF1">FDA. Clinical Review. 2020.</div></li><li><div class="bk_ref" id="Tafasitamab.REF2">
|
|
<a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2020/761163Orig1s000MultidisciplineR.pdf</a>
|
|
|
|
<div>
|
|
<i>(FDA Summary of the data the safety and efficacy of tafasitamab, submitted in support of the application for approval as therapy of diffuse large B cell lymphoma [DLBCL] mentions that tafasitamab had “acceptable safety” and ALT elevations arose in 11.1% of 222 treated patients in the safety cohort, but that all elevations were less than 5 times ULN, and no patient developed clinically apparent liver injury attributable to the monoclonal antibody).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.jurczak.2018.1266">Jurczak
|
|
W, Zinzani
|
|
PL, Gaidano
|
|
G, Goy
|
|
A, Provencio
|
|
M, Nagy
|
|
Z, Robak
|
|
T, et al.
|
|
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
|
Ann Oncol.
|
|
2018;29:1266-1272.
|
|
[<a href="/pmc/articles/PMC5961010/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5961010</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29444231" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29444231</span></a>]<div><i>(Among 92 adults with relapsed or refractory non-Hodgkin lymphoma treated with tafasitamab, the objective response rate and duration of response was highest in patients with DLBCL, and while adverse events were common, they were largely infusion reactions, myelosuppression, and infections; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.salles.2020.978">Salles
|
|
G, Duell
|
|
J, González Barca
|
|
E, Tournilhac
|
|
O, Jurczak
|
|
W, Liberati
|
|
AM, Nagy
|
|
Z, et al.
|
|
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
|
|
Lancet Oncol.
|
|
2020;21:978-988.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32511983" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32511983</span></a>]<div><i>(Among 81 adults with relapsed or refractory DLBCL treated with tafasitamab and lenalidomide in 28 day cycles for a median of 13 months, the objective response rate was 60% [complete 43%] and adverse events arose in all patients, which were serious in 51%, comprising largely myelosuppression and infections, but the authors state that therapy “was well tolerated”; aminotransferase elevations arose in 3% but no details provided).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.hoy.2020.1731">Hoy
|
|
SM. Tafasitamab: first approval.
|
|
Drugs.
|
|
2020;80:1731-1737.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32946059" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32946059</span></a>]<div><i>(Review of the history of development, mechanism of action, pharmacology, clinical efficacy, and safety of tafasitamab shortly after its approval for use in the United States, mentions that virtually all recipients develop adverse events that are serious in half, but that tafasitamab has a “manageable safety profile”; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.delgado.2021.e666">Delgado
|
|
J, Papadouli
|
|
I, Sarac
|
|
SB, Moreau
|
|
A, Hovgaard
|
|
D, Gisselbrecht
|
|
C, Enzmann
|
|
H, et al.
|
|
The European Medicines Agency review of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma.
|
|
Hemasphere.
|
|
2021;5:e666.
|
|
[<a href="/pmc/articles/PMC8601272/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8601272</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34805769" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34805769</span></a>]<div><i>(Summary of the European Medicines Agency review of tafasitamab for DLBCL mentions that adverse events arose in all 222 patients exposed to tafasitamab in the safety cohort, but that there were no cases of drug induced liver injury “and only 5 cases of elevated liver enzymes, all considered unrelated to therapy”).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF7">In brief: tafasitamab (Monjuvi) for diffuse large B-cell. Med Lett Drugs Ther. 20237;65(1682):e133.<div><i>(Concise review of the mechanism of action, clinical efficacy, safety, and costs of tafasitamab shortly after its approval for use in relapsed or refractory DLBCL; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.belada.2023.1348">Belada
|
|
D, Kopeckova
|
|
K, Bergua Burgues
|
|
JM, Stevens
|
|
D, André
|
|
M, Persona
|
|
EP, Pichler
|
|
P, et al.
|
|
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
|
|
Blood.
|
|
2023;142:1348-1358.
|
|
[<a href="/pmc/articles/PMC10651865/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10651865</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37369099" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37369099</span></a>]<div><i>(Among 83 adults with untreated DLBCL treated with open label tafasitamab and R-CHOP with or without lenalidomide, the overall response rate was slightly higher with lenalidomide [82% vs 76%] as was the serious adverse event rate [51% vs 42%]; no mention of ALT elevations of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.qualls.2023.2327">Qualls
|
|
DA, Lambert
|
|
N, Caimi
|
|
PF, Merrill
|
|
M, Pullarkat
|
|
P, Godby
|
|
RC, Bond
|
|
DA, et al.
|
|
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
|
|
Blood.
|
|
2023;142:2327-2331.
|
|
[<a href="/pmc/articles/PMC10797539/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10797539</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37738563" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37738563</span></a>]<div><i>(Among 178 patients with DLBCL treated with tafasitamab and lenalidomide in routine practice at 11 institutions, the overall response rate was only 31% and progression-free survival only 1.9 months, while adverse event rates were similar including aminotransferase elevations in 1.3%).</i></div></div></li><li><div class="bk_ref" id="Tafasitamab.REF.duell.2024.553">Duell
|
|
J, Abrisqueta
|
|
P, Andre
|
|
M, Gaidano
|
|
G, Gonzales-Barca
|
|
E, Jurczak
|
|
W, Kalakonda
|
|
N, et al.
|
|
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
|
|
Haematologica.
|
|
2024;109:553-566.
|
|
[<a href="/pmc/articles/PMC10828760/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10828760</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37646664" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37646664</span></a>]<div><i>(A final 5 year follow up on the open label registration trial of tafasitamab and lenalidomide for relapsed or refractory DLBCL [Salles 2020] demonstrated an objective response rate of 58%, complete response rate of 41%, progression-free survival of 11.6 months and overall survival of 33.5 months with no new safety signals and no mention of ALT elevations or hepatotoxicity, but one case of reactivation of hepatitis B was reported for the initial year of tafasitamab and lenalidomide therapy; no details provided).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK604847_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">May 14, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tafasitamab. [Updated 2024 May 14].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Tafamidis/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Tafenoquine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobTafasitamabTc"><div id="Tafasitamab.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK604847/table/Tafasitamab.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tafasitamab.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Tafasitamab.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Tafasitamab.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Tafasitamab.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Tafasitamab.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Tafasitamab.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tafasitamab</td><td headers="hd_h_Tafasitamab.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/381127365" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">1422527-84-1</a>
|
|
</td><td headers="hd_h_Tafasitamab.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Tafasitamab.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|